As of Aug 18
| +0.01 / +0.02%|
The 16 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 41.64, with a high estimate of 52.98 and a low estimate of 35.68. The median estimate represents a -11.67% decrease from the last price of 47.14.
The current consensus among 17 polled investment analysts is to Sell stock in Novozymes A/S. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.